Tel Aviv, Tel Aviv District, Israel The main department of described VC is located in the Tel Aviv. The fund was located in Asia if to be more exact in Israel.
For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Orchard Therapeutics, Deciphera Pharmaceuticals Among the most successful fund investment fields, there are Biotechnology, Genetics. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups.
This organization was formed by Mori Arkin. We also calculated 3 valuable employees in our database.
The fund is constantly included in less than 2 deals per year. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2018. This Sphera Global Healthcare Fund works on 71 percentage points more the average amount of lead investments comparing to the other organizations. The top activity for fund was in 2017. Deals in the range of 50 - 100 millions dollars are the general things for fund.
The usual cause for the fund is to invest in rounds with 8-9 partakers. Despite the Sphera Global Healthcare Fund, startups are often financed by F-Prime Capital, UCL Technology Fund, Temasek Holdings. The meaningful sponsors for the fund in investment in the same round are Venrock, Viking Global Investors, Temasek Holdings. In the next rounds fund is usually obtained by Oxford Finance LLC.
Related Funds
| Fund Name | Location |
| Alta Communications | Boston, Massachusetts, United States |
| China CITIC Bank | Beijing, Beijing, China |
| Chongqing Rural Commercial Bank | China, Chongqing, Chongqing Shi |
| GE Asset Management | Connecticut, Stamford, United States |
| Innovatech Grand Montreal | Canada, Montréal, Quebec |
| Jenner LLP | - |
| Jiancheng Xinxi | Beijing, China, Haidian |
| Ketang Ziben | China, Guangdong, Shenzhen |
| Mubadala Ventures | Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates |
| Renbao Yuanwang | Beijing, Beijing, China |
| RMM | Belgium, Gent, Oost-Vlaanderen |
| Shenzhen Centralcon Investment Holding | China, Futian, Guangdong |
| Shuttle Fund | New York, New York, United States |
| Siena Lending Group | Connecticut, Stamford, United States |
| Skagen Group | Richardson, Texas, United States |
| SocialCapital | California, San Francisco, United States |
| Touradji Capital Management | New York, New York, United States |
| Visum SGPS | - |
| Yingfu Tianxia Touzi | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Frontier Medicines | $88M | 19 Jul 2021 | San Francisco, California, United States | ||
| $73M | 30 Mar 2021 | Palo Alto, California, United States | |||
Werewolf Therapeutics | $72M | 07 Jan 2021 | Cambridge, Massachusetts, United States | ||
LianBio | $310M | 29 Oct 2020 | Shanghai, China | ||
Frontier Medicines | $88M | 19 Jul 2019 | - | ||
Orchard Therapeutics | $150M | 13 Aug 2018 | London, England, United Kingdom | ||
Deciphera Pharmaceuticals | $52M | 01 Jun 2017 | Massachusetts, United States |
– Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1 and B2 financing.
– The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.
– In conjunction with this round of financing, Oceanpine CEO and managing partner Dave Chenn joins the Immune-Onc Board of Directors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Frontier Medicines | $88M | 19 Jul 2021 | San Francisco, California, United States | ||
| $73M | 30 Mar 2021 | Palo Alto, California, United States | |||
Werewolf Therapeutics | $72M | 07 Jan 2021 | Cambridge, Massachusetts, United States | ||
LianBio | $310M | 29 Oct 2020 | Shanghai, China | ||
Frontier Medicines | $88M | 19 Jul 2019 | - | ||
Orchard Therapeutics | $150M | 13 Aug 2018 | London, England, United Kingdom | ||
Deciphera Pharmaceuticals | $52M | 01 Jun 2017 | Massachusetts, United States |
